The Stop TB Private Sector Constituency
The Private Sector Constituency (PSC) brings together companies and business leaders committed to ending tuberculosis and advancing global health. Within the Stop TB Partnership Board, the PSC represents and amplifies private-sector perspectives, ensuring that enterprise, innovation, and implementation experience contribute to collective efforts to defeat TB.
What we do
- Facilitate collaboration: connecting companies with partners across public, multilateral, and civil-society sectors.
- Mobilize engagement and resources: encouraging private-sector participation, investment, technical expertise, and innovation in the TB response.
- Promote awareness and participation: inviting new businesses to join and supporting those already taking action in affected communities and workforces.
Our members
PSC members include pharmaceutical and diagnostics leaders, medical-device companies, digital and technology innovators (including AI and data partners), and enterprises operating in high-burden settings or with TB-affected workforces. Together, they apply their expertise, networks, and reach to deliver practical solutions—from supply chains and digital tools to workplace health and community partnerships.
Why it matters
Ending TB requires every sector to play its part. The private sector contributes scale, creativity, and operational strength that complement the work of governments and civil society. Through the PSC, these contributions are connected and amplified—helping turn business capability into lasting public-health impact.
Why TB Still Matters
Tuberculosis remains one of the world’s deadliest infectious diseases. In 2023, an estimated 10.8 million people fell ill with TB and about 1.25 million died, according to the World Health Organization. While progress in high-income countries has reduced cases dramatically since the mid-20th century, the burden of TB continues to fall disproportionately on low- and middle-income nations, where access to diagnosis and treatment is still uneven.
The rise of drug-resistant tuberculosis has further complicated global efforts. In 2023, there were roughly 400,000 new cases of multidrug- or rifampicin-resistant TB (MDR/RR-TB), and fewer than half of those affected accessed effective treatment. Left unchecked, drug-resistant TB could cost the global economy trillions of dollars in lost productivity by mid-century and remains one of the leading drivers of antimicrobial resistance worldwide.
Our Priorities
innovation & access
From breakthrough research to real-world delivery, innovation only matters when it reaches people who need it most. Our members work to close the gap between discovery and access supporting smarter regulation, open collaboration, and faster adoption of new tools and approaches.
strong health systems
Investing in TB strengthens health systems far beyond the disease itself.
PSC members help build capacity that improves resilience, efficiency, and preparedness from digital infrastructure and supply chains to workforce training.
By treating TB investments as long-term health investments, our members reinforce the foundation for universal health coverage and future pandemic readiness.
TB FINANCING
Ending TB depends on sustainable, predictable financing. The private sector plays a crucial role, mobilizing new resources, building partnerships, and helping shape models that deliver impact at scale. Through collaboration and advocacy, we aim to position TB funding within broader global health financing reforms, ensuring that commitments translate into lasting change.
Advocacy & Communication
Driving visibility and collective action is central to PSC’s mission. We amplify the voice of business in the global fight against TB engaging decision-makers, partners, and the public through evidence-based advocacy and strategic communications. By sharing success stories and championing innovation, we help position the private sector as a trusted, indispensable partner in ending TB.